The human microbiome industry is poised for exponential growth and transformative advancements in the near future.…
Author: admin
Global Healthcare Interoperability Solutions Market Report 2023: Government Initiatives to Enhance Patient Care and Safety Fuel the Sector
The “Healthcare Interoperability Solutions Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering. This report provides strategists, marketers…
Roche introduces navify® Sample Tracking for labs to track patient test samples before even reaching lab premises
Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces navify® Sample Tracking, its cloud-based digital solution helping laboratories mitigate the…
Biochips Market size is set to grow by USD 43,273.01 million from 2022 to 2027; The growing use of personalized medicines to boost the market – Technavio
The global biochips market size is estimated to grow by USD 43,273.01 million from 2022 to 2027, according to Technavio. The…
Kelyniam Global Releases Q1 Financials, Announces Licensing Agreement with Bioplate for Osteopore Products
Kelyniam Global (OTC: KLYG), a leading maker of custom cranial implants, today announced results for its quarter ended March 31, 2023. “I’m pleased to announce that…
Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic
BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that they have submitted a Marketing Authorisation…
Medtronic Extravascular ICD global clinical trial results reinforce device safety and effectiveness
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced longer-term follow-up results of its investigational…
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company’s key electrophysiology and cardiac…
CureScience™ Institute Summer Scholar Bioinformatics Training Program
CureScience™ Institute, a San Diego, California based non-profit 501(c)(3) dedicated to accelerating cures based on a combination of…
Abbott Unveils Late-Breaking Data Showing the World’s First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study,…